Skip to main content
Clinical Trials/NCT01739686
NCT01739686
Completed
Not Applicable

Collaborative Care to Alleviate Symptoms and Adjust to Illness in Chronic Heart Failure (CASA) Trial

Denver Research Institute3 sites in 1 country317 target enrollmentAugust 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Chronic Heart Failure
Sponsor
Denver Research Institute
Enrollment
317
Locations
3
Primary Endpoint
Difference in Kansas City Cardiomyopathy Questionnaire (KCCQ) overall score
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

Chronic heart failure is an important public health problem as it is a leading cause of disability, hospitalization, death, and costs. People who live with advanced chronic heart failure suffer from numerous symptoms that affect their daily lives. The investigators are conducting a randomized clinical trial to evaluate a symptom management and psychosocial care intervention to improve health status (symptom burden, functioning, and quality of life). The results will be directly relevant to patients and families who suffer with this illness, as well as to providers, payers, and other researchers.

Registry
clinicaltrials.gov
Start Date
August 2012
End Date
December 2015
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

David Bekelman, M.D.

Associate Professor of Medicine

Denver Research Institute

Eligibility Criteria

Inclusion Criteria

  • Age 18 years of age or older
  • Able to read and understand English
  • Consistent access to a telephone
  • Patients have a primary care or other provider who is willing to facilitate intervention medical recommendations
  • A diagnosis of heart failure with at least one of the following:
  • \[hospitalization primarily for heart failure in the year prior (including current); taking at least 20 mg oral furosemide (or equivalent) daily in a single or divided dose; Brain natriuretic peptide(BNP) ≥ 100 or N-terminal prohormone of brain natriuretic peptide(NT-proBNP) ≥ 500; EF≤40%\]
  • Report a low health status (KCCQ-SF≤70)
  • Bothered by at least one target symptom:
  • \[Pain; Depression; Fatigue; Breathlessness\]

Exclusion Criteria

  • Previous diagnosis of dementia
  • Active substance abuse or dependence, defined by either a diagnosis of abuse or dependence or an AUDIT-C ≥ 8, or self-reported substance abuse in the past 3 months
  • Comorbid metastatic cancer
  • Nursing home resident
  • Heart Transplant recipient
  • LVAD recipient

Outcomes

Primary Outcomes

Difference in Kansas City Cardiomyopathy Questionnaire (KCCQ) overall score

Time Frame: 6 months

The KCCQ is a self-administered questionnaire that measures heart failure-specific health status. The KCCQ is reliable, sensitive to clinical change, and predicts hospitalization and mortality. The study will test whether there is a difference in KCCQ overall score between the intervention and control groups at 6 months.

Secondary Outcomes

  • Difference in pain using the PEG(6 months)
  • Difference in Patient Health Questionnaire-9 (PHQ-9) score(6 months)
  • Difference in Satisfaction with Healthcare(6 months)
  • Change in Dyspnea(6 months)
  • Difference in symptom distress, measured using the General Symptom Distress Scale(6 months)
  • Difference in Self-care of Heart Failure Index (SCHFI)(12 months)
  • Change in Sheehan Disability Scale(12 months)
  • Change in Quality of Life at the End of Life (QUAL-E)(12 months)
  • Change in fatigue using the Patient Reported Outcomes Measurement Information System (PROMIS) fatigue measure(6 months)

Study Sites (3)

Loading locations...

Similar Trials